Replication of the POET-COPD Trial in Healthcare Claims Data
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 8,716
- 试验地点
- 1
- 主要终点
- Time to first COPD exacerbation
研究概览
简要总结
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
详细描述
This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to replicate, as closely as is possible in healthcare insurance claims data, the trial listed below/above. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates according to standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 40 Years 至 120 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age greater or equal than 40: days [0,0]
- •Diagnosis of COPD: days [-All Data, 0]
- •History of at least 1 COPD exacerbation within the past year requiring treatment with antibiotics and/or systemic steroids and/or requiring hospitalization: days [-365, -28]
排除标准
- •Patients with 3 diagnosis of asthma: days [-180, 0]
- •Patients with current severe cardiovascular disorders (Heart Transplantation, LVAD/Implantable heart, Pulmonary hypertension/other pulmonary disease) and use of systemic corticosteroid medication at unstable doses: days [-365, 0]
- •Patients with any respiratory infection (Acute respiratory infections, pneumonia and influenza) or COPD exacerbation: days [-28, 0]
- •Exclude use of salmeterol or tiotropium containing inhaler use [-180, 0]
研究组 & 干预措施
Salmeterol inhaler
Reference group
干预措施: Salmeterol (Drug)
Tiotropium
Exposure group
干预措施: Tiotropium (Drug)
结局指标
主要结局
Time to first COPD exacerbation
时间窗: [Time Frame: To censoring or study completion, up to 365 days]
Time to first COPD exacerbation
次要结局
- All-cause death([Time Frame: To censoring or study completion, up to 365 days])
研究者
Shirley Vichy Wang
Assistant Professor
Brigham and Women's Hospital
